mRCC: promising new combinations lead to disruption in L1 and L2

Syndicated Studies, Oncology

Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of advanced/metastatic renal cell carcinoma (mRCC) in the first line. While new drugs have expanded the treatment options, significant opportunities remain in this highly competitive market.

COVID-19 road to recovery: 5 key insights from our syndicated study

COVID-19, Syndicated Studies

As the global number of infected cases surpasses 46 million (Nov 2, 2020), there is a non-stop...

Social Media Insights: ASCO 2020 Part 2

Social Media Listening

The American Society of Oncologists (ASCO) annual meeting is a major fixture in the global...

Welcoming the new-look AplusA website!

AplusA News, Digital

You might have noticed that our site looks a little different. We wanted to share the story...

DLBCL Patient Insights in the US and EU5

hemato-oncology, DLBCL market

When working on a new or existing brand within the DLBCL market it's important to have up to...

Social Media Insights: ASCO 2020 Part 1

Social Media Listening

The American Society of Oncologists (ASCO) annual meeting is a major fixture in the global...

Social Media Listening: Insights from Healthcare conferences

Market Research Industry, Social Media Listening

Healthcare conferences provide unique opportunities to gain first-hand insights from otherwise...

DLBCL Treatment Performance in EU5 and US

hemato-oncology, Tracking Studies, DLBCL market

The DLBCL market is undergoing a period of change, and the relative performance of the various...

DLBCL Market Overview

hemato-oncology, Tracking Studies, DLBCL market

Following the release of our latest ebook, this is the first blog post in this series focusing...

New AplusA eBook Covers the DLBCL Market

AplusA News, hemato-oncology

Introducing the latest eBook in AplusA's Hemato-Oncology series